8-K: MEI Pharma to Explore Strategic Alternatives, Discontinues Voruciclib Clinical Development

MEI Pharma is evaluating strategic options, including a potential wind-down, and will discontinue clinical development of voruciclib while continuing non-clinical activities.

Summary

• MEI Pharma's Board of Directors has initiated a strategic review to explore options such as potential transactions or an orderly wind-down to maximize asset value.
• The company will discontinue the clinical development of voruciclib, an oral CDK9 inhibitor, but will continue non-clinical activities related to its drug candidates.
• The company intends to use a corporate presentation to describe the status of the voruciclib program.
• The presentation includes forward-looking statements and should be considered in the context of the company's SEC filings and other public announcements.
• The company is focusing on relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) with voruciclib in combination with venetoclax.
• The estimated cost to complete Phase 1 and Phase 2 studies with approximately 56 patients by the end of 2025 is around $4.7 million.
• Voruciclib has shown on-target effects, decreasing Mcl-1 and RNA Pol II phosphorylation, and has demonstrated anti-leukemic activity after venetoclax failure.
• The company has observed a decrease in peripheral blasts with voruciclib and venetoclax, but a rebound when voruciclib is stopped.
• The company is evaluating a 21-day voruciclib dosing schedule to prevent blast rebound.
• The company has completed a dose escalation/expansion study of voruciclib plus venetoclax in R/R AML, showing clinical activity and a well-tolerated regimen.
• The company has worldwide rights to voruciclib and has several patents covering the composition of matter and methods of use.
• Voruciclib is being investigated for potential use in other hematologic indications and solid tumors.

Sentiment

Score: 3

Explanation: The document contains significant negative news, including the potential wind-down of the company and the discontinuation of clinical development for their lead drug candidate. While there are some positive aspects related to the drug's mechanism and early clinical data, the overall sentiment is negative due to the strategic review and potential for company closure.

Positives

• Voruciclib has demonstrated on-target biological activity by decreasing Mcl-1 and RNA Pol II phosphorylation.
• The combination of voruciclib and venetoclax has shown anti-leukemic activity in patients who have progressed after venetoclax treatment.
• The company has observed a decrease in peripheral blasts with the combination therapy.
• Voruciclib has been generally well-tolerated in heavily pre-treated patients with R/R AML.
• MEI Pharma has a strong intellectual property position with multiple patents for voruciclib.
• Voruciclib has potential applications in other hematologic malignancies and solid tumors.

Negatives

• The company is considering a potential wind-down, indicating financial challenges.
• The clinical development of voruciclib is being discontinued, which may impact future revenue potential.
• There was a blast rebound observed when voruciclib was stopped, requiring a change in dosing schedule.
• The company has paused enrollment in the 3-week dosing schedule study for strategic reasons.
• Patients with adverse risk AML and specific molecular mutations had low disease control rates.

Risks

• The company's strategic review could lead to a wind-down, resulting in loss of investment.
• Discontinuing clinical development of voruciclib may reduce the company's value.
• The company may face challenges in securing additional funding to continue operations.
• The company's drug candidates may not achieve regulatory approval.
• There are risks associated with the company's dependence on collaboration or contractual arrangements.
• The company faces competition from other pharmaceutical companies.
• The company may not be able to protect its patents or proprietary rights.

Future Outlook

The company intends to complete the dose optimization of voruciclib in combination with venetoclax and potentially conduct a Phase 2 study in 2025. The company is also exploring the potential of voruciclib in other hematologic and solid tumor indications.

Management Comments

• The Board of Directors has determined to begin an evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind-down of the Company, if necessary, in order to maximize the value of its assets.

Industry Context

The document highlights the need for new treatment options for R/R AML patients, particularly those who have failed venetoclax. The company positions voruciclib as a potential solution, noting it is the only oral CDK9 inhibitor in clinical development in combination with venetoclax for AML. The document also mentions other companies developing CDK9 inhibitors, indicating a competitive landscape.

Comparison to Industry Standards

• The document compares the response rates of voruciclib plus venetoclax to current standard of care treatments for R/R AML, noting that a 20% response rate would be a significant improvement over the 6-12.5% seen with non-mutation targeted therapies.
• The document lists several other companies developing CDK9 inhibitors, such as Cyclacel Pharma, Edgewood Oncology, Sellas, Kronos Bio, and Prelude Therapeutics, highlighting the competitive landscape in this area.
• The document notes that voruciclib is the only oral CDK9 inhibitor in clinical development in combination with venetoclax for AML, which is a differentiator.
• The document references studies showing that high levels of Mcl-1 are associated with poor prognosis and resistance to venetoclax in AML, which supports the rationale for targeting Mcl-1 with voruciclib.

Stakeholder Impact

• Shareholders face significant risk due to the potential wind-down of the company.
• Employees may face job losses if the company is wound down.
• Patients may lose access to a potential new treatment option for AML.
• Suppliers and creditors may face financial losses if the company is wound down.

Next Steps

• The company will continue to evaluate strategic alternatives.
• The company will continue non-clinical activities related to its drug candidates.
• The company may reactivate enrollment in the voruciclib study in September 2024.
• The company may conduct a Phase 2 study at the recommended Phase 2 dose in 2025.

Key Dates

Keywords

voruciclib, MEI Pharma, CDK9 inhibitor, AML, venetoclax, clinical development, strategic alternatives, R/R AML, Mcl-1, RNA Pol II, patent, hematologic malignancies, solid tumors